The Ah receptor regulates growth factor expression in head and neck squamous cell carcinoma cell lines

Molecular Carcinogenesis

Volumn 53, Issue 10, 2014, Pages 765-776

  John, Kaarthik ^a,b   Lahoti, Tejas S ^a   Wagner, Kelly ^a   Hughes, Jarod M ^a   Perdew, Gary H ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b DUPONT COMPANY   (United States)

Author keywords

AHR; Antagonist; Aryl hydrocarbon receptor; Dioxin; Growth factors; Head and neck cancer

Indexed keywords

2 METHYL 2H PYRAZOLE 3 CARBOXYLIC ACID (2 METHYL 4 O TOLYLAZOPHENYL)AMIDE; 2-METHYL-2H-PYRAZOLE-3-CARBOXYLIC ACID (2-METHYL-4-O-TOLYLAZOPHENYL)AMIDE; AROMATIC HYDROCARBON RECEPTOR; AZO COMPOUND; DIOXIN; EPIDERMAL GROWTH FACTOR; EPIREGULIN; FIBROBLAST GROWTH FACTOR 2; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR A; PLATELET-DERIVED GROWTH FACTOR A; PYRAZOLE DERIVATIVE;

AHR; ANTAGONIST; ARTICLE; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; GROWTH FACTORS; HEAD AND NECK CANCER; HEAD AND NECK TUMOR; HUMAN; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

AHR; ANTAGONIST; ARYL HYDROCARBON RECEPTOR; DIOXIN; GROWTH FACTORS; HEAD AND NECK CANCER;

AZO COMPOUNDS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; PLATELET-DERIVED GROWTH FACTOR; PYRAZOLES; RECEPTORS, ARYL HYDROCARBON;

EID: 84908365407     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22032     Document Type: Article

References (49)

1. Beischlag TV, Luis Morales J, Hollingshead BD, Perdew GH. The aryl hydrocarbon receptor complex and the control of gene expression. Crit Rev Eukaryot Gene Expr 2008;18:207-250.
2. Denison MS, Soshilov AA, He G, DeGroot DE, Zhao B. Exactly the same but different: Promiscuity and diversity in the molecular mechanisms of action of the aryl hydrocarbon (dioxin) receptor. Toxicol Sci 2011;124:1-22.
3. Stejskalova L, Dvorak Z, Pavek P. Endogenous and exogenous ligands of aryl hydrocarbon receptor: Current state of art. Curr Drug Metab 2011;12:198-212.
4. Abel J, Haarmann-Stemmann T. An introduction to the molecular basics of aryl hydrocarbon receptor biology. Biol Chem 2010;391:1235-1248.
5. Dietrich C, Kaina B. The aryl hydrocarbon receptor (AhR) in the regulation of cell-cell contact and tumor growth. Carcinogenesis 2010;31:1319-1328.
6. Ramadoss P, Marcus C, Perdew GH. Role of the aryl hydrocarbon receptor in drug metabolism. Expert Opin Drug Metab Toxicol 2005;1:9-21.
7. Tanos R, Patel RD, Murray IA, Smith PB, Patterson AD, Perdew GH. Aryl hydrocarbon receptor regulates the cholesterol biosynthetic pathway in a dioxin response element-independent manner. Hepatology 2012;55:1994-2004.
8. Veldhoen M, Duarte JH. The aryl hydrocarbon receptor: Finetuning the immune-response. Curr Opin Immunol 2010;22: 747-752.
9. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144:646-674.
10. DiNatale BC, Schroeder JC, Francey LJ, Kusnadi A, Perdew GH. Mechanistic insights into the events that lead to synergistic induction of interleukin 6 transcription upon activation of the aryl hydrocarbon receptor and inflammatory signaling. J Biol Chem 2010;285:24388-24397.
11. DiNatale BC, Schroeder JC, Perdew GH. Ah receptor antagonism inhibits constitutive and cytokine inducible IL6 production in head and neck tumor cell lines. Mol Carcinog 2010;50:173-183.
12. Hollingshead BD, Beischlag TV, DiNatale BC, Ramadoss P, Perdew GH. Inflammatory signaling and aryl hydrocarbon receptor mediate synergistic induction of interleukin 6 in MCF- 7 cells. Cancer Res 2008;68:3609-3617.
13. Dinatale BC, Smith K, John K, Krishnegowda G, Amin SG, Perdew GH. Ah receptor antagonism represses head and neck tumor cell aggressive phenotype. Mol Cancer Res 2012;10: 1369-1379.
14. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 2008;371:1695-1709.
15. Price KA, Cohen EE. Current treatment options for metastatic head and neck cancer. Curr Treat Options Oncol 2012;13: 35-46.
16. Kurzweg T, Mockelmann N, Laban S, Knecht R. Current treatment options for recurrent/metastatic head and neck cancer: A post-ASCO 2011 update and review of last year's literature. Eur Arch Otorhinolaryngol 2012;269:2157-2167.
17. Kim SH, Henry EC, Kim DK, et al. Novel compound 2-methyl- 2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)- amide (CH-223191) prevents 2,3,7,8-TCDD-induced toxicity by antagonizing the aryl hydrocarbon receptor. Mol Pharmacol 2006;69:1871-1878.
18. Aaronson SA. Growth factors and cancer. Science 1991;254: 1146-1153.
19. Favoni RE, de Cupis A. The role of polypeptide growth factors in human carcinomas: New targets for a novel pharmacological approach. Pharmacol Rev 2000;52:179-206.
20. Applied Biosystems: Guide to Performing Relative Quantitation of Gene Expression Using Real-Time Quantitative PCR. 2004.
21. Carlson JM, Chakravarty A, DeZiel CE, Gross RH. SCOPE: A web server for practical de novo motif discovery. Nucleic Acids Res 2007;35:W259-W264.
22. Kawashiri S, Kumagai S, Kojima K, Harada H, Yamamoto E. Development of a new invasion and metastasis model of human oral squamous cell carcinomas. Eur J Cancer B Oral Oncol 1995;31B:216-221.
23. Yoo GH, Subramanian G, Boinpally RR, et al. An in vivo evaluation of docetaxel delivered intratumorally in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2005;131:418-429.
24. Yoo GH, Subramanian G, Piechocki MP, et al. Effect of docetaxel on the surgical tumor microenvironment of head and neck cancer in murine models. Arch Otolaryngol Head Neck Surg 2008;134:735-742.
25. Marur S, Forastiere AA. Head and neck cancer: Changing epidemiology, diagnosis, and treatment. Mayo Clin Proc 2008;83:489-501.
26. http://www.cancer.net/patient/Cancer+Types/Head+and+ Neck + Cancer?sectionTitle = Statistics.
27. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf.
28. Peng TL, Chen J, Mao W, Song X, Chen MH. Aryl hydrocarbon receptor pathway activation enhances gastric cancer cell invasiveness likely through a c-Jun-dependent induction of matrix metalloproteinase-9. BMC Cell Biol 2009;10:27.
29. Ishida M, Mikami S, Kikuchi E, et al. Activation of the aryl hydrocarbon receptor pathway enhances cancer cell invasion by upregulating the MMP expression and is associated with poor prognosis in upper urinary tract urothelial cancer. Carcinogenesis 2010;31:287-295.
30. Zudaire E, Cuesta N, Murty V, et al. The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple human cancers. J Clin Invest 2008;118:640-650.
31. Schlezinger JJ, Liu D, Farago M, et al. A role for the aryl hydrocarbon receptor in mammary gland tumorigenesis. Biol Chem 2006;387:1175-1187.
32. Hall JM, Barhoover MA, Kazmin D, McDonnell DP, Greenlee WF, Thomas RS. Activation of the aryl-hydrocarbon receptor inhibits invasive and metastatic features of human breast cancer cells and promotes breast cancer cell differentiation. Mol Endocrinol 2010;24:359-369.
33. Fan Y, Boivin GP, Knudsen ES, Nebert DW, Xia Y, Puga A. The aryl hydrocarbon receptor functions as a tumor suppressor of liver carcinogenesis. Cancer Res 2010;70:212-220.
34. Jaffrain-Rea ML, Angelini M, Gargano D, et al. Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: Pathological and clinical implications. Endocr Relat Cancer 2009;16:1029-1043.
35. Yadav A, Kumar B, Datta J, Teknos TN, Kumar P. IL-6 promotes head and neck tumor metastasis by inducing epithelialmesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol Cancer Res 2011;9:1658-1667.
36. Chow G, Tauler J, Mulshine JL. Cytokines and growth factors stimulate hyaluronan production: Role of hyaluronan in epithelial to mesenchymal-like transition in non-small cell lung cancer. J Biomed Biotechnol 2010;2010:485468.
37. Hart K, Landvik NE, Lind H, Skaug V, Haugen A, Zienolddiny S. A combination of functional polymorphisms in the CASP8, MMP1, IL10 and SEPS1 genes affects risk of non-small cell lung cancer. Lung Cancer 2011;71:123-129.
38. Rajkumar T, Sabitha K, Vijayalakshmi N, et al. Identification and validation of genes involved in cervical tumourigenesis. BMC Cancer 2011;11:80.
39. Pennanen PT, Sarvilinna NS, Toimela T, Ylikomi TJ. Inhibition of FOSL1 overexpression in antiestrogen-resistant MCF-7 cells decreases cell growth and increases vacuolization and cell death. Steroids 2011;76:1063-1068.
40. Zhang H, Pan Y, Zheng L, et al. FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. Cancer Res 2011;71:3257-3267.
41. Kim SH, Park YY, Kim SW, Lee JS, Wang D, DuBois RN. ANGPTL4 induction by prostaglandin E2 under hypoxic conditions promotes colorectal cancer progression. Cancer Res 2011;71:7010-7020.
42. Goustin AS, Leof EB, Shipley GD, Moses HL. Growth factors and cancer. Cancer Res 1986;46:1015-1029.
43. Witsch E, Sela M, Yarden Y. Roles for growth factors in cancer progression. Physiol Behav 2010;25:85-101.
44. Shigeishi H, Higashikawa K, Hiraoka M, et al. Expression of epiregulin, a novel epidermal growth factor ligand associated with prognosis in human oral squamous cell carcinomas. Oncol Rep 2008;19:1557-1564.
45. Marshall ME, Hinz TK, Kono SA, et al. Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells. Clin Cancer Res 2011;17:5016-5025.
46. Patel RD, Kim DJ, Peters JM, Perdew GH. The aryl hydrocarbon receptor directly regulates expression of the potent mitogen epiregulin. Toxicol Sci 2006;89:75-82.
47. Zhao B, Degroot DE, Hayashi A, He G, Denison MS. CH223191 is a ligand-selective antagonist of the Ah (Dioxin) receptor. Toxicol Sci 2010;117:393-403.
48. Liu Z, Hartman YE, Warram JM, et al. Fibroblast growth factor receptor mediates fibroblast-dependent growth in EMMPRINdepleted head and neck cancer tumor cells. Mol Cancer Res 2011;9:1008-1017.
49. Xie G, Peng Z, Raufman JP. Src-mediated aryl hydrocarbon and epidermal growth factor receptor cross talk stimulates colon cancer cell proliferation. AmJ Physiol Gastrointest Liver Physiol 2012;302:G1006-G1015.